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A chest computed tomographic angiography 
(CTA) was done which revealed a large saddle 
pulmonary embolus straddling the main pulmonary 
arterial trunk at its bifurcation and extending into the 
main right and left pulmonary arteries (Figure 2). He 
was commenced on subcutaneous low-molecular-
weight heparin (LMWH) while delivery of 
tenectaplase was being awaited. He also received 
intravenous morphine for his chest pain. He 
subsequently received a single dose of intravenous 
tenectaplase and was continued on subcutaneous 
LMWH and oral warfarin with the LMWH 
withdrawn after a few days. He was anticoagulated 
to a target international normalized ratio (INR) of 
2.5 – 3.  
Within 24 hours of thrombolysis, pulses on 
the left upper extremity became palpable. Brachial 
blood pressure also became recordable. Oxygen 
saturation (by pulse oximetry) also increased in both 
upper extremities to 88% – 90%. Breathlessness and 
chest pain also diminished greatly and he no longer 
needed morphine. A repeat chest CTA scan showed a 
marked reduction in the size of the saddle embolus. 
He was subsequently discharged after a few more 
days on oral warfarin. However, few weeks after 
discharge, patient suddenly developed worsening 
breathlessness at home and was taken to a nearby 
hospital but all attempts are resuscitation were 
unsuccessful and the patient died.
Figure 1: Doppler ultrasound scan (USS) of the left 
femoral vein showing dilatation and non-
compressibility of the vessel (arrow ).
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CASE REPORT
A 45-year-old apparently healthy man presented to the Cardiology Clinic with a 6-month history of 
recurrent breathlessness and chest pain. Prior to referral, he had been treated for asthma and chronic 
obstructive pulmonary disease with no improvement. A cardiovascular cause of his recurrent breathlessness 
was queried and he was then sent to the cardiologist. An additional history of transient unilateral right leg pain 
and swelling 7 months earlier was obtained. This occurred following a long-haul flight from Nigeria to 
Zambia. He was not known to be hypertensive or diabetic.
On examination, he had a resting tachycardia which ranged between 114 and 140 beats per minute. 
Pulses were however not palpable on his left upper limb. Blood pressure was also not recordable on the same 
limb. Blood pressure measured over the brachial artery on the right was 118/78 mmHg. His neck veins were 
distended and the pulmonary component of his second heart sound was loud. Electrocardiography done 
showed sinus tachycardia with incomplete right bundle branch block. Chest x-ray showed multiple sites of 
sub-pleural infarction. Echocardiography showed mild systolic and diastolic dysfunction with an ejection 
fraction of 49%. Full blood count, fasting blood sugar, fasting serum lipids, electrolytes, urea, creatinine and 
uric acid were all normal. D-dimer was however elevated. Doppler ultrasound scan (USS) revealed a large 
deep vein thrombus (DVT) in the left femoral vein with associated non-compressibility of the vessel
 (Figure 1).
Figure 2:  Chest computed tomographic 
angiography (CTA) scan showing a large saddle 
pulmonary embolus straddling the main pulmonary 
arterial trunk at its bifurcation and extending into the 
main right and left pulmonary arteries.
DISCUSSION
Venous thromboembolism (VTE) clinically 
manifested as deep vein thrombosis (DVT) and 
pulmonary embolism (PE), is a common cause of 
increased morbidity and mortality. PE represents a 
spectrum of syndromes ranging from small 
peripheral emboli causing pleuritic pain to massive 
PE resulting in cardiogenic shock or cardiac arrest.
Saddle PE is a form of large pulmonary 
thromboembolism that straddles the main 
pulmonary arterial trunk at its bifurcation, usually 
extending into the main right and left pulmonary 
arteries. Its incidence among patients diagnosed 
with PE is approximately 2.6%. Such proximal 
thrombus may be regarded as an unstable, “in-
t rans i t”  embolus ,  which  can  f ragment  
spontaneously or secondary to treatment and 
obstruct multiple, distal pulmonary arteries. It 
remains unclear whether this may further increase 
haemodynamic compromise. Also, it is unknown 
whether saddle PE requires modification of clinical 
management.
Saddle PE frequently results in significant 
hemodynamic instability and signals the potential 
f o r  i m m i n e n t  h e m o d y n a m i c  c o l l a p s e .  
Unfortunately, the most common presenting 
symptoms of dyspnoea followed by syncope are 
relatively non-specific. Consequently, a high index 
of suspicion and emergent diagnosis and treatment 
are of critical importance.
There are well-known risk factors for 
development of PE, including venous stasis, obesity, 
trauma, advanced age, confirmed DVT and 
hypercoagulable states. However, a study of the 
International Cooperative Pulmonary Embolism 
Registry (ICOPER) found certain comorbidities to 
be specifically associated with massive PE, 
including congestive heart failure (CHF), renal 
dysfunction, decreased left ventricular systolic 
ejection fraction, cardiopulmonary disease and right 
ventricular thrombi.
Virchow's triad of local trauma to the vessel 
wall, hypercoagulability and stasis of blood leads to 
thrombus formation in the leg veins. As thrombi 
form in the deep veins of the legs, pelvis or arms, 
they may dislodge and embolize to the pulmonary 
arteries with potentially serious consequences. The 
most common sources of pulmonary emboli are the 
pelvic veins or deep veins of the thigh.
The incidence of mortality after PE has been 
reported to be as high as 300,000 per year, with a 
three-month mortality of 15% - 18%. While most 
patients with acute PE survive, possible long-term 
sequelae include chronic thromboembolic 
pulmonary hypertension and chronic leg pain and 
swelling. Right-sided heart failure is the usual cause 
of death from PE, and right ventricular dysfunction 
serves as a crucially important warning for a 
possible adverse outcome. The mortality rate at one 
year is three times higher in patients with right 
ventricular dysfunction compared to those with 
normal right ventricular function. Chronic 
pulmonary hypertension affects approximately 4% 
of patients within two years after a first episode of 
symptomatic PE.
A bedside transthoracic or transoesophageal 
echocardiogram can be used to demonstrate signs of 
right ventricular pressure overload and right 
ventricular hypokinesis and/or dilatation. The 
McConnell sign of PE is normal apical motion of the 
right ventricle despite hypokinesis of its free wall. 
Also, a bedside echocardiogram may eliminate 
other causes of shock, such as myocardial infarction, 
cardiac tamponade and aortic dissection.
Treatment  of  saddle PE includes 
anticoagulants, thrombolytics and catheter-based or 
surgical embolectomy. In the absence of any large 
scale data, treatment should be individualized 
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according to clinical status, evidence of right 
ventricular dysfunction and risk of bleeding. 
Anticoagulants (heparin and warfarin) remain an 
integral part of all treatment plans.
It has been suggested that saddle PE should 
be urgently treated surgically. However, other 
authors have reported successful recovery following 
less aggressive treatment comprising intravenous 
thrombolysis or even routine anticoagulation. It was 
even suggested that capture of a large 
thromboembolus at the level of bifurcation of the 
main pulmonary artery might provide protection 
from complete obstruction of the pulmonary arteries 
and therefore prevent sudden death.
Whether or not patients undergo primary 
therapy (f ibr inolysis  or  embolectomy),  
anticoagulation is a critical component of the 
management of PE. Parenteral anticoagulation with 
either low molecular weight heparin or 
unfractionated heparin should be administered, 
unless contraindicated. Heparin accelerates the 
action of antithrombin III, thereby preventing 
additional thrombus formation and permitting 
endogenous fibrinolysis to dissolve some of the clot. 
Unfractionated heparin, which can be rapidly 
reversed, is preferred in patients undergoing 
fibrinolysis or embolectomy. Low-molecular-
weight heparins (LMWHs) such as enoxaparin have 
been shown to be as safe and effective as intravenous 
unfractionated heparin.
Fondaparinux is a synthetic pentasaccharide 
with anti-Xa activity approved by the Food and 
Drug Administration (FDA) for the initial treatment 
of VTE including PE. In haemodynamically stable 
patients with acute symptomatic PE, fondaparinux 
is as safe and effective as intravenous unfractionated 
heparin. Unlike intravenous unfractionated heparin, 
fondaparinux is administered in a fixed dose and 
does not require dose adjustment with laboratory 
coagulation tests. 
Oral vitamin K antagonists such as warfarin 
have remained the mainstay of outpatient 
anticoagulation for VTE. Oral anticoagulation is 
usually initiated simultaneously with heparin, 
LMWH or fondaparinux and overlapped for at least 
5 days until full therapeutic efficacy has been 
achieved. The target international normalized ratio 
(INR) is between 2.0 and 3.0 for the majority of 
patients with PE. The optimal duration of 
anticoagulation depends on the risk of recurrent 
VTE. In patients without reversible causes for DVT 
or PE, VTE represents a chronic illness with a high 
risk of recurrence after completion of standard 
anticoagulation.
Thrombolysis can be lifesaving in patients 
with massive PE, cardiogenic shock or overt 
hemodynamic instability. Thrombolytic agents 
accelerate the lysis of the PE. Currently, the Food 
and Drug Administration (FDA) recommends 
thrombolysis for the treatment of “massive PE.” 
“Massive” universally indicates cardiogenic shock 
secondary to PE, but also can suggest profound 
hypoxaemia (like in the index case) or impending 
respiratory failure. Patients treated with 
thrombolytic therapy show rapid improvement of 
right ventricular function and pulmonary perfusion 
which may lead to a lower rate of early recurrent PE 
and a decrease the late sequela of chronic pulmonary 
hypertension.
Severa l  s tud ies  have  shown the  
physiological benefits of thrombolytics in cases of 
PE such as improvement in haemodynamics, 
oxygenation and a lower incidence of early PE 
recurrence, but they have not shown a clear long-
term mortality benefit. According to the results of 
Phase 1 of the Urokinase Pulmonary Embolism 
Trial, haemodynamically stable patients treated with 
anticoagulation alone have similar outcomes as 
those treated with thrombolytics. Importantly, the 
difference in the degree of clot resolution between 
the two groups progressively decreases after 24 
hours, such that both treatment groups have no 
difference in clot burden at five or 14 days or even 
several months. Other thrombolytics like alteplase 
and tenectaplase are also in use.
Surgical embolectomy may be considered 
for patients in whom fibrinolysis is contraindicated. 
Additional indications include paradoxical 
embolism, persistent right heart thrombi and 
haemodynamic or respiratory compromise 
requiring cardiopulmonary resuscitation. In 
specialized centres caring for patients with massive 
PE, surgical embolectomy has been demonstrated to 
be a safe and effective treatment technique. 
Catheter-based pulmonary embolectomy is an 
emerging modality for the primary therapy of acute 
PE. Catheter-based strategies are considered when 
fibrinolysis and open surgical embolectomy are 
contraindicated. In general, catheter-based 
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embolectomy is most successful when applied to 
fresh thrombus within the first 5 days of symptoms 
of PE.
Inferior vena cava (IVC) filters are indicated 
for patients in whom anticoagulation is 
contraindicated, those who experience recurrent PE 
despite adequate anticoagulation and those 
undergoing open surgical embolectomy. IVC filters 
are associated with an increased incidence of DVT. 
Although further studies are required, a recent 
analysis from ICOPER demonstrated a significant 
reduction in 90-day mortality associated with IVC 
filters. Retrievable IVC filters should be considered 
for patients with transient contraindications to 
anticoagulation.
Rapid recognition and treatment are very 
important to prevent severe morbidity and mortality 
after PE. Current methods used to prevent DVT and 
PE have significantly reduced the incidence of fatal 
PE. Treatments that combine mechanical 
prophylaxis such as, sequential compression 
devices or IVC filters, with LMWH appear to be 
most effective. However, even patients on 
appropriate prophylaxis are still developing DVT 
and PE. Future research will hopefully help with 
better prevention and treatment of PE.
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